Renaissance Technologies’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-226,500
| Closed | -$4.08M | – | 3859 |
|
|
2020
Q2 | $4.08M | Sell |
226,500
-712,497
| -76% | -$9.91M | ﹤0.01% | 1770 |
|
|
2020
Q1 | $6.7M | Buy |
938,997
+775,755
| +475% | +$9.68M | 0.01% | 1398 |
|
|
2019
Q4 | $3.9M | Buy |
+163,242
| New | +$4.5M | ﹤0.01% | 2004 |
|
|
2019
Q3 | – | Sell |
-10,058
| Closed | -$273K | – | 3850 |
|
|
2019
Q2 | $273K | Buy |
+10,058
| New | +$315K | ﹤0.01% | 3208 |
|
|
2018
Q2 | – | Sell |
-366,400
| Closed | -$12M | – | 3650 |
|
|
2018
Q1 | $12M | Buy |
366,400
+13,600
| +4% | +$597K | 0.01% | 1251 |
|
|
2017
Q4 | $17.2M | Sell |
352,800
-175,700
| -33% | -$8.89M | 0.02% | 1051 |
|
|
2017
Q3 | $28.6M | Buy |
528,500
+151,300
| +40% | +$8.88M | 0.03% | 679 |
|
|
2017
Q2 | $21.2M | Buy |
+377,200
| New | +$15.1M | 0.03% | 818 |
|
|
2016
Q4 | – | Sell |
-161,500
| Closed | -$3.67M | – | 3575 |
|
|
2016
Q3 | $3.67M | Sell |
161,500
-187,900
| -54% | -$4.41M | 0.01% | 1802 |
|
|
2016
Q2 | $8.25M | Sell |
349,400
-125,400
| -26% | -$3.1M | 0.02% | 1266 |
|
|
2016
Q1 | $9.69M | Buy |
474,800
+335,700
| +241% | +$10.7M | 0.02% | 1161 |
|
|
2015
Q4 | $7.16M | Buy |
139,100
+115,300
| +484% | +$5.59M | 0.02% | 1220 |
|
|
2015
Q3 | $1.01M | Sell |
23,800
-3,600
| -13% | -$174K | ﹤0.01% | 2371 |
|
|
2015
Q2 | $1.25M | Sell |
27,400
-32,550
| -54% | -$1.31M | ﹤0.01% | 2329 |
|
|
2015
Q1 | $2.28M | Buy |
+59,950
| New | +$2.06M | ﹤0.01% | 1861 |
|
Renaissance Technologies's PTLA Position: Q3 2020 in Review
Renaissance Technologies sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 226,500 shares — an estimated $4.08M sold.
Renaissance Technologies first reported a position in PTLA in Q1 2015 and held it in 15 quarters. The position peaked at $28.6M in Q3 2017. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Renaissance Technologies reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Renaissance Technologies sold 226,500 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $4.08M.
- Renaissance Technologies first reported a position in Portola Pharmaceuticals, Inc. in Q1 2015 and held it in 15 quarters.
- Renaissance Technologies's Portola Pharmaceuticals, Inc. position peaked at $28.6M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Renaissance Technologies's 13F filing for Q3 2020, filed 13 Nov 2020.